|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 2992017 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14791454.3 |
| Date of filing the European patent application | 2014-05-02 | |
| (97) | Date of publication of the European application | 2016-03-09 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-18 |
| (46) | Date of publication of the claims translation | 2021-02-25 |
| (86) | Number | PCT/US2014/036525 |
| Date | 2014-05-02 |
| (87) | Number | WO 2014/179664 |
| Date | 2014-11-06 |
| (30) | Number | Date | Country code |
| 201361818755 P | 2013-05-02 | US |
| (72) |
KING, David J., US
KEHRY, Marilyn, US
|
| (73) |
AnaptysBio, Inc.,
10770 Wateridge Circle, Suite 210, San Diego, CA 92121,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Antikūnai nukreipti prieš programuotos žūties baltymą-1 (PD-1) |
| ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 (PD-1) |
| Payment date | Validity (years) | Amount | |
| 2025-04-23 | 12 | 289.00 EUR |
| 2026-05-02 |